vs
凯雷集团（CG）与爱德华生命科学（EW）财务数据对比。点击上方公司名可切换其他公司
凯雷集团的季度营收约是爱德华生命科学的1.2倍（$1.9B vs $1.6B），爱德华生命科学净利率更高（23.1% vs 18.8%，领先4.3%），凯雷集团同比增速更快（84.1% vs 16.7%），过去两年凯雷集团的营收复合增速更高（66.2% vs 9.7%）
凯雷集团是美国知名跨国企业，核心业务涵盖私募股权投资、另类资产管理及金融服务领域。截至2023年，公司管理资产总规模达4260亿美元，是全球另类资管行业的重要参与者。
爱德华生命科学是总部位于美国加利福尼亚州尔湾的医疗科技企业，专注于人工心脏瓣膜及血流动力学监测领域，其研发的Sapien经导管主动脉心脏瓣膜采用牛组织材质，搭配球囊扩张式钴铬合金支架，可通过导管完成植入。
CG vs EW — 直观对比
营收规模更大
CG
是对方的1.2倍
$1.6B
营收增速更快
CG
高出67.4%
16.7%
净利率更高
EW
高出4.3%
18.8%
两年增速更快
CG
近两年复合增速
9.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.9B | $1.6B |
| 净利润 | $358.1M | $380.7M |
| 毛利率 | — | 78.0% |
| 营业利润率 | 24.3% | 1.8% |
| 净利率 | 18.8% | 23.1% |
| 营收同比 | 84.1% | 16.7% |
| 净利润同比 | 69.8% | 6.8% |
| 每股收益（稀释后） | $0.96 | $0.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CGEW
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.9B | $1.6B | ||
| Q3 25 | $332.7M | $1.6B | ||
| Q2 25 | $1.6B | $1.5B | ||
| Q1 25 | $973.1M | $1.4B | ||
| Q4 24 | $1.0B | $1.4B | ||
| Q3 24 | $2.6B | $1.4B | ||
| Q2 24 | $1.1B | $1.4B |
净利润CGEW
| Q1 26 | — | $380.7M | ||
| Q4 25 | $358.1M | $91.2M | ||
| Q3 25 | $900.0K | $291.1M | ||
| Q2 25 | $319.7M | $333.2M | ||
| Q1 25 | $130.0M | $358.0M | ||
| Q4 24 | $210.9M | $385.6M | ||
| Q3 24 | $595.7M | $3.1B | ||
| Q2 24 | $148.2M | $366.3M |
毛利率CGEW
| Q1 26 | — | 78.0% | ||
| Q4 25 | — | 78.1% | ||
| Q3 25 | — | 77.8% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.7% | ||
| Q4 24 | — | 78.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 79.9% |
营业利润率CGEW
| Q1 26 | — | 1.8% | ||
| Q4 25 | 24.3% | 9.6% | ||
| Q3 25 | 25.8% | 19.8% | ||
| Q2 25 | 28.0% | 26.8% | ||
| Q1 25 | 17.6% | 27.9% | ||
| Q4 24 | 25.7% | 22.6% | ||
| Q3 24 | 29.9% | 25.9% | ||
| Q2 24 | 20.5% | 26.8% |
净利率CGEW
| Q1 26 | — | 23.1% | ||
| Q4 25 | 18.8% | 5.8% | ||
| Q3 25 | 0.3% | 18.7% | ||
| Q2 25 | 20.3% | 21.7% | ||
| Q1 25 | 13.4% | 25.3% | ||
| Q4 24 | 20.4% | 27.8% | ||
| Q3 24 | 22.6% | 226.7% | ||
| Q2 24 | 13.9% | 26.7% |
每股收益（稀释后）CGEW
| Q1 26 | — | $0.66 | ||
| Q4 25 | $0.96 | $0.16 | ||
| Q3 25 | $0.00 | $0.50 | ||
| Q2 25 | $0.87 | $0.56 | ||
| Q1 25 | $0.35 | $0.61 | ||
| Q4 24 | $0.56 | $0.65 | ||
| Q3 24 | $1.63 | $5.13 | ||
| Q2 24 | $0.40 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.1B | — |
| 总资产 | $29.1B | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CGEW
| Q1 26 | — | — | ||
| Q4 25 | $2.0B | $4.2B | ||
| Q3 25 | $2.2B | $3.8B | ||
| Q2 25 | $1.3B | $4.1B | ||
| Q1 25 | $1.2B | $3.9B | ||
| Q4 24 | $1.3B | $4.0B | ||
| Q3 24 | $1.4B | $4.4B | ||
| Q2 24 | $914.8M | $2.0B |
股东权益CGEW
| Q1 26 | — | — | ||
| Q4 25 | $7.1B | $10.3B | ||
| Q3 25 | $6.8B | $10.2B | ||
| Q2 25 | $6.7B | $10.5B | ||
| Q1 25 | $6.4B | $10.1B | ||
| Q4 24 | $6.3B | $10.0B | ||
| Q3 24 | $6.3B | $9.5B | ||
| Q2 24 | $5.7B | $7.4B |
总资产CGEW
| Q1 26 | — | — | ||
| Q4 25 | $29.1B | $13.7B | ||
| Q3 25 | $27.1B | $13.3B | ||
| Q2 25 | $25.1B | $13.5B | ||
| Q1 25 | $24.1B | $13.0B | ||
| Q4 24 | $23.1B | $13.1B | ||
| Q3 24 | $22.7B | $13.0B | ||
| Q2 24 | $22.3B | $10.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2B | — |
| 自由现金流经营现金流 - 资本支出 | $-1.2B | — |
| 自由现金流率自由现金流/营收 | -65.1% | — |
| 资本支出强度资本支出/营收 | 2.2% | — |
| 现金转化率经营现金流/净利润 | -3.34× | — |
| 过去12个月自由现金流最近4个季度 | $-3.4B | — |
8季度趋势，按日历期对齐
经营现金流CGEW
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $450.9M | ||
| Q3 25 | $-1.6B | $573.7M | ||
| Q2 25 | $-168.8M | $290.2M | ||
| Q1 25 | $-352.1M | $280.4M | ||
| Q4 24 | $-352.8M | $-127.5M | ||
| Q3 24 | $791.9M | $351.8M | ||
| Q2 24 | $-1.3B | $371.5M |
自由现金流CGEW
| Q1 26 | — | — | ||
| Q4 25 | $-1.2B | $353.5M | ||
| Q3 25 | $-1.6B | $516.2M | ||
| Q2 25 | $-186.3M | $240.9M | ||
| Q1 25 | $-368.8M | $224.4M | ||
| Q4 24 | $-379.5M | $-177.3M | ||
| Q3 24 | $772.8M | $299.9M | ||
| Q2 24 | $-1.3B | $286.1M |
自由现金流率CGEW
| Q1 26 | — | — | ||
| Q4 25 | -65.1% | 22.5% | ||
| Q3 25 | -475.7% | 33.2% | ||
| Q2 25 | -11.8% | 15.7% | ||
| Q1 25 | -37.9% | 15.9% | ||
| Q4 24 | -36.8% | -12.8% | ||
| Q3 24 | 29.3% | 22.1% | ||
| Q2 24 | -120.4% | 20.9% |
资本支出强度CGEW
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 6.2% | ||
| Q3 25 | 7.0% | 3.7% | ||
| Q2 25 | 1.1% | 3.2% | ||
| Q1 25 | 1.7% | 4.0% | ||
| Q4 24 | 2.6% | 3.6% | ||
| Q3 24 | 0.7% | 3.8% | ||
| Q2 24 | 1.7% | 6.2% |
现金转化率CGEW
| Q1 26 | — | — | ||
| Q4 25 | -3.34× | 4.94× | ||
| Q3 25 | -1732.78× | 1.97× | ||
| Q2 25 | -0.53× | 0.87× | ||
| Q1 25 | -2.71× | 0.78× | ||
| Q4 24 | -1.67× | -0.33× | ||
| Q3 24 | 1.33× | 0.11× | ||
| Q2 24 | -8.57× | 1.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CG
| Fund Management Fee | $606.8M | 32% |
| Other | $528.7M | 28% |
| Global Private Equity Segment | $307.3M | 16% |
| Global Credit Segment | $238.0M | 13% |
| Carlyle Alp Invest Segment | $124.6M | 7% |
| Incentive Fee | $55.4M | 3% |
| Fee Related Performance Revenues | $29.2M | 2% |
| Investment Advice | $11.1M | 1% |
EW
暂无分部数据
